Myosin Inhibitor Deal Benchmarks in Cardiovascular

Median Upfront

$788M

Range: $429M - $1.1B

Total Deal Value

$4.0B

Range: $2.6B - $5.3B

Royalty Rate

10.1% - 20.3%

Tiered up to 24.3%

Dev Milestones

$699M

Range: $472M - $927M

Model Your Deal

Market Analysis

Myosin Inhibitor therapies in cardiovascular have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 myosin inhibitor asset in cardiovascular is $788M, with total deal values reaching $4.0B. Development milestones average $699M, while regulatory milestones contribute $889M.

The cardiovascular myosin inhibitor landscape is characterized by moderate competitive intensity with renewed interest in novel mechanisms and genetic targets. RNA-based therapies, PCSK9 approaches, and novel anticoagulants are driving a resurgence in cardiovascular deal activity. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for myosin inhibitor cardiovascular deals range from 10.1% to 20.3% at the base tier, with tiered escalation reaching 14.1%-24.3% on blockbuster sales. Commercial milestones averaging $1.6B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a myosin inhibitor cardiovascular licensing deal?

Based on our analysis, Phase 2 myosin inhibitor licensing deals in cardiovascular average $788M in upfront payments, with a range of $429M to $1.1B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for myosin inhibitor cardiovascular transactions?

The median total deal value for Phase 2 myosin inhibitor assets in cardiovascular is $4.0B, ranging from $2.6B to $5.3B. This includes development milestones ($699M), regulatory milestones ($889M), and commercial milestones ($1.6B).

What royalty rates are standard for myosin inhibitor deals in cardiovascular?

Base royalty rates for myosin inhibitor cardiovascular transactions range from 10.1% to 20.3%, with tiered escalations reaching 14.1%-24.3% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in myosin inhibitor cardiovascular deals?

Myosin Inhibitor cardiovascular deals allocate approximately 80% of total deal value to milestones. Development milestones ($699M) make up the largest share, followed by commercial milestones ($1.6B) and regulatory milestones ($889M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Cardiovascular

View

Monoclonal Antibody in Cardiovascular

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included